Individuals with mild cognitive impairment (MCI) are at increased risk to develop dementia.^[@R1]^ Yet, up to 25% of individuals with MCI revert to normal cognition (NC).^[@R2],[@R3]^ Although improved cognition seems to be a positive event, individuals reverting from MCI remain at increased risk to develop dementia compared to NC individuals.^[@R1],[@R4],[@R5]^ Timely identification of individuals with a higher risk will increase prognostic certainty for patients and be useful for health care planning.

In individuals with NC and MCI, low memory function, abnormal biomarkers for Alzheimer disease (AD), and neurodegeneration predict dementia.^[@R6],[@R7]^ While MCI reverters deviate from the common clinical trajectory, the same disease processes may be underlying. Our aim was to investigate whether MCI reverters who subsequently showed clinical decline have more abnormal AD markers than MCI reverters who remain stable.

Methods {#s1}
=======

Participants {#s1-1}
------------

Data analyzed were obtained from the Alzheimer\'s Disease Neuroimaging Initiative (ADNI) database ([adni.loni.usc.edu](http://adni.loni.usc.edu), downloaded on August 9, 2017). From the individuals with at least 2 years clinical follow-up, we selected all individuals with prevalent and incident MCI reverting to NC with additional follow-up after reversion.^[@R8]^ The ADNI was launched in 2003 as a public--private partnership, led by Principal Investigator Michael W. Weiner, MD. The goal of ADNI has been to test whether serial MRI, PET, other biological markers, and clinical and neuropsychological assessment can measure progression to MCI and early AD. Next to the primary analyses in ADNI, we selected from the Amsterdam Dementia Cohort (ADC) all MCI reverters with follow-up after reversion. Similar clinical and biomarker assessments are presented for this small, independent clinical sample for illustration purposes only (for cohort and biomarker methods^[@R9]^).

Standard protocol approvals, registrations, and participant consents {#s1-2}
--------------------------------------------------------------------

All protocols were approved by an ethical review board and participants signed informed consent.

Clinical markers and *APOE* {#s1-3}
---------------------------

All individuals had baseline data on age, sex, and education. *APOE* genotype was dichotomized into ɛ4 carriers and noncarriers. Overall cognitive status was assessed by the Mini-Mental State Examination, memory by the Rey Auditory Verbal Learning Test immediate (0--75) and delayed total recall (0--15), executive function by the Trial-Making Test A and B (seconds), and depressive symptoms by the Geriatric Depression Scale (GDS) (0--15). Subthreshold depression was classified as GDS \>4.^[@R10]^

Biomarkers of AD and neurodegeneration {#s1-4}
--------------------------------------

We studied CSF β-amyloid 1--42 (Aβ~1-42~) and total tau (t-tau) (Luminex in ADNI^[@R11]^; Innotest in ADC^[@R12]^) and amyloid PET (florbetapir and Pittsburgh compound B \[PiB\]) as markers for AD pathology. PiB scans were harmonized to florbetapir by new value = PiB standard uptake value ratio (SUVr) \* 0.67 + 0.15.^[@R13]^ For imaging markers of neurodegeneration, we studied FDG-PET, hippocampal volume (HV; UCSF in Freesurfer v4.4/v5.1), normalized to total intracranial volume, and white matter hyperintensity volume.^[@R14]^ Cut points for abnormality for dichotomized analysis in ADNI were as follows: CSF Aβ~1-42~ \< 192 pg/mL, CSF t-tau \> 93 pg/mL, amyloid PET SUVr \> 1.10, FDG-PET SUVr METAROI \< 1.21, and raw HV \< 6,732 mm^3^ (see references [@R11], [@R12], [@R15], and [@R16] for procedures and processing). Data collected within 1 year before or after MCI diagnosis were included.

Statistical analysis {#s1-5}
--------------------

MCI reverters with NC at last follow-up and MCI reverters with subsequent decline were compared on clinical and biomarkers using χ^2^, Wilcoxon, and *t* tests when appropriate. We report results unadjusted and adjusted for age, sex, education, and *APOE* ε4 genotype with univariate linear regression models, and scaling of continuous outcomes, to facilitate comparability of effects.

Data-sharing statement {#s1-6}
----------------------

Data used for this study are available from the corresponding author, upon reasonable request.

Results {#s2}
=======

In ADNI, 757 individuals with prevalent or incident MCI had been followed for at least 2 years ([figure 1](#F1){ref-type="fig"}). Of these, 77 (10%) reverted to NC, and 61 (79%) had additional follow-up available. After 3.2 ± 2.2 years (mean ± SD), 16 (24%) had converted to MCI, and 3 (5%) to dementia. One individual was excluded, due to missing data.

![Flow diagram: Sample selection, Alzheimer\'s Disease Neuroimaging Initiative\
DX = diagnosis; FU = follow-up visit; MCI = mild cognitive impairment; NC = cognitively normal.](NEUROLOGY2018942573FF1){#F1}

MCI reverters who showed subsequent clinical decline were on average 5 years older than reverters remaining NC, and had, adjusted for age, sex, education, and *APOE*, higher and more often abnormal AD biomarkers (amyloid PET and CSF t-tau), less impaired memory, and higher GDS scores ([table](#T1){ref-type="table"} and [figure 2](#F2){ref-type="fig"}). Follow-up after reversion seemed slightly shorter for stable MCI reverters (*p* = 0.11). Repeating analyses including this covariate did not essentially change the results (table e-1, [doi.org/10.5061/dryad.04n8502](https://doi.org/10.5061/dryad.04n8502)).
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![Standardized **β**s: Alzheimer disease (AD) clinical markers and biomarkers for decliner group\
Immediate and delayed recall of the Rey Auditory Verbal Learning Test, Trail-Making Test (TMT), Geriatric Depression Scale (GDS), white matter hyperintensities (WMH), and hippocampal volume (HV). Models were adjusted for age, sex, education, and *APOE* ε4.](NEUROLOGY2018942573FF2){#F2}

Post hoc analyses further showed that biomarkers of MCI reverters were on average more similar to NC than nonreverting MCI, except for amyloid, which was more often abnormal in MCI reverters than in NC (table e-2, [doi.org/10.5061/dryad.04n8502](https://doi.org/10.5061/dryad.04n8502)). Still, MCI reverters showed higher clinical progression rates (110/1,000 person-years) compared to baseline NC (52/1,000 person-years, hazard ratio \[95% confidence interval\] 2.3 \[1.4--4.0\], *p* = 0.002) (table e-3 and figure e-1, [doi.org/10.5061/dryad.04n8502](https://doi.org/10.5061/dryad.04n8502)). The biomarker associations with progression were similar for NC and MCI reverters, whereas associations with progression and cognitive test scores were less consistent (table e-4 and figure e-2, [doi.org/10.5061/dryad.04n8502](https://doi.org/10.5061/dryad.04n8502)).

Outcome of MCI reverters in clinical ADC cohort {#s2-1}
-----------------------------------------------

In the ADC, of 735 patients with MCI and a follow-up visit, 75 (10%) reverted to NC. Twenty-six (35%) patients had 1.6 ± 0.8 years (mean ± SD) follow-up available after reversion, after which 24 (92%) remained NC and 2 (8%) had dementia. Small group size precluded formal statistical testing. The 2 decliners had abnormal CSF Aβ~1-42~ and t-tau ([table](#T1){ref-type="table"}). The majority of individuals remaining NC had normal CSF Aβ~1-42~ (80%) and t-tau (85%). Thirty-two percent of the stable reverters showed baseline subthreshold depression.

Discussion {#s3}
==========

Age and AD biomarkers are associated with decline in patients with MCI who initially reverted to normal cognition. MCI reverters showed higher clinical progression rates than NC individuals, which is in line with previous reports.^[@R1],[@R4]^ MCI reverters with subsequent decline had an increased amyloid PET burden and CSF tau compared to reverters remaining normal. Between amyloid markers, amyloid PET showed a significant association with the subsequent decline group in MCI reverters, while this association was significant for CSF Aβ~1-42~ in NC. Although previous research suggests that CSF amyloid becomes abnormal before PET,^[@R17],[@R18]^ the findings are in line with other reports that this may not apply to all individuals,^[@R19],[@R20]^ which contributes to the notion that CSF Aβ~1-42~ and amyloid PET may represent different AD-related processes.

An outstanding question is why individuals with underlying AD temporarily improved. Our results suggest that at baseline, MCI reverters were more similar to NC than nonreverting MCI. Furthermore, biomarker values associated with subsequent decline were similar for reverting MCI and NC, while cognitive measures were less consistent. Possibly, reverters with decline received an MCI diagnosis very early in their clinical disease course, as their biomarker profiles were like the nonreverting MCI. A modest improvement, for example, due to learning effects, resolving of (subthreshold) depressive symptoms, or measurement error, may have contributed to reclassification as normal. Here we observed that when AD is present, such improvement is often not lasting.

Furthermore, it remains unclear as to why individuals who reverted and remained NC over time were initially diagnosed with MCI. Aside neurodegenerative diseases, depressive symptoms are a common cause of MCI. Low depressive symptoms scores in ADNI reflect inclusion criteria. In the ADC, subthreshold depression was more common. Another possibility is that distress or insecurity led to a suboptimal performance. The question remains how to deal with the classification of these individuals in the context of AD progression research, when MCI is often regarded as an intermediate disease stage. A practical implementation could be to classify reverting MCI with normal biomarkers as NC. Alternatively, including stability of the diagnosis in the classification has been suggested.^[@R4]^

A limitation of this study is the relatively short follow-up time, and so we cannot exclude the possibility that some individuals in the stable group may progress again. Compared to population-based studies, reversion rates in both cohorts were low.^[@R3]^ Possibly, this reflects that clinicians will not easily reverse a known diagnosis. Reversion rates may even be lower, because we based reversion rates on individuals with MCI who met our inclusion criteria. Individuals with MCI excluded from these analyses as they were lost to follow-up were somewhat older and more cognitively impaired, which are characteristics that associate with decline^[@R1]^ (table e-5, [doi.org/10.5061/dryad.04n8502](https://doi.org/10.5061/dryad.04n8502)). Although further replication in large population-based studies is necessary, our results suggest that AD biomarkers aid in the prognosis of MCI reverters, and could help to identify those with a good short term prognosis and those likely to decline again in the longer term.
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